{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:15:58Z","timestamp":1767791758459,"version":"3.49.0"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018262","name":"Intercept Pharmaceuticals","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>American Association for the Study of Liver Disease guidelines recommend regular testing of alkaline phosphatase (ALP) among patients with primary biliary cholangitis (PBC) to monitor disease progression and response to treatment with ursodeoxycholic acid (UDCA), but previous studies have shown that adherence to recommended testing intervals is low. We used data from the Fibrotic Liver Disease (FOLD) Consortium to evaluate rates of adherence among US routine care patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PBC cases were confirmed with chart abstraction. Patients from three FOLD sites (Henry Ford Health (Detroit, MI), Kaiser Permanente-Southern California (Los Angeles, California) and Kaiser Permanente-Northwest (Portland, Oregon)) were observed from 1 January 2018 through 31 December 2021. We divided our evaluation of adherence to monitoring guidelines into two segments: (1) the first 12 months post-UDCA initiation; and (2) &gt;12 months post-UDCA initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1756 patients were identified for the 2018\u20132021 period; 67 patients did not receive UDCA and were excluded from the sample. A total of 1689 patients were included in one or both segments (segment 1: 740, segment 2: 1689). Only 52% of patients received appropriate ALP testing to ascertain response to UDCA after roughly 1 year of treatment; rates were significantly higher among patients with specialist care compared with those without (54% vs 45%, p=0.001). For the period following the first year of UDCA treatment, the observed monitoring rate was 67%, where hepatology or gastroenterology specialist care was associated with significantly higher rates of monitoring (65%\u201378%) compared with those without care from a specialist (30%\u201357%, p&lt;0.0001) with the same level of comorbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a large US PBC cohort, there were concerning levels of non-adherence to recommended biochemical monitoring. Receipt of care from a specialist was associated with higher rates of monitoring. Strategies to increase rates of biochemical testing are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-001899","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:55:14Z","timestamp":1761123314000},"page":"e001899","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of adherence to guidelines for biochemical monitoring and ursodeoxycholic acid treatment response in a retrospective cohort of US patients with primary biliary cholangitis"],"prefix":"10.1136","volume":"12","author":[{"given":"Stuart C","family":"Gordon","sequence":"first","affiliation":[{"name":"Wayne State University School of Medicine, Detroit, MI, USA"},{"name":"Department of Gastroenterology and Hepatology, Henry Ford Health, Detroit, MI, USA"},{"name":"School of Human Medicine, Michigan State University, East Lansing, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandeep","family":"Sahota","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Center for Health Research, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihe G","family":"Daida","sequence":"additional","affiliation":[{"name":"Center for Integrated Health Care Research, Honolulu, HI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loralee B","family":"Rupp","sequence":"additional","affiliation":[{"name":"Center for Health Policy And Health Services Research, Henry Ford Health, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri","family":"Trudeau","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Henry Ford Health, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Melkonian","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Henry Ford Health, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L","family":"Bowlus","sequence":"additional","affiliation":[{"name":"University of California Davis School of Medicine, Sacramento, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-6428","authenticated-orcid":false,"given":"Mei","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Human Medicine, Michigan State University, East Lansing, MI, USA"},{"name":"Department of Public Health Sciences, Henry Ford Health, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026010701054311000_12.1.e001899.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145"},{"key":"2026010701054311000_12.1.e001899.2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"2026010701054311000_12.1.e001899.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"2026010701054311000_12.1.e001899.4","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10276-6"},{"key":"2026010701054311000_12.1.e001899.5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/HEP.0000000000001166","article-title":"Primary biliary cholangitis: Personalizing second-line therapies","volume":"82","author":"Levy","year":"2025","journal-title":"Hepatology"},{"key":"2026010701054311000_12.1.e001899.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100931","article-title":"Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery","volume":"6","author":"Abbas","year":"2024","journal-title":"JHEP Rep"},{"key":"2026010701054311000_12.1.e001899.7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026010701054311000_12.1.e001899.8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026010701054311000_12.1.e001899.9","unstructured":"Breiman L , Friedman J , Trees S . Classification and regression trees. 1st edn. New York: Chapman and Hall, 1984."},{"key":"2026010701054311000_12.1.e001899.10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/CLEP.S262558","article-title":"Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis","volume":"12","author":"Lu","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2026010701054311000_12.1.e001899.11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S136134","article-title":"Validity of an automated algorithm using diagnosis and procedure codes to identify decompensated cirrhosis using electronic health records","volume":"9","author":"Lu","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2026010701054311000_12.1.e001899.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.031"},{"key":"2026010701054311000_12.1.e001899.13","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"2026010701054311000_12.1.e001899.14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2026010701054311000_12.1.e001899.15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"2026010701054311000_12.1.e001899.16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104150","article-title":"A change of paradigm in PBC: Pursuing normal alkaline phosphatase","volume":"82","author":"Lleo","year":"2022","journal-title":"EBioMedicine"},{"key":"2026010701054311000_12.1.e001899.17","article-title":"Beyond the Surface: Unveiling Hidden Hurdles to Primary Biliary Cholangitis Care","volume":"16","author":"Shamaa","year":"2024","journal-title":"Cureus"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-001899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:06:15Z","timestamp":1767776775000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-001899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjgast-2025-001899"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-001899","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}